The biopharmaceutical company, which was co-founded by Ionis Pharmaceuticals, has secured funding in an Andera Partners-led round.

Dynacure, a France-based centronuclear myopathy therapy developer backed by biopharmaceutical company Ionis Pharmaceuticals, raised €47m ($55m) yesterday in a funding round led by private equity firm Andera Partners.

French government-owned investment bank BPIfrance also took part in the round, as did Pontifax, Kurma Partners and Idinvest Partners.

Founded in 2016, Dynacure is working on Dyn101, a treatment for centronuclear myopathy, a group of rare and often fatal conditions that cause muscle weakness and wasting. Dyn101 is being developed in collaboration…